290 related articles for article (PubMed ID: 23499664)
1. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.
Auclair AL; Martel JC; Assié MB; Bardin L; Heusler P; Cussac D; Marien M; Newman-Tancredi A; O'Connor JA; Depoortère R
Neuropharmacology; 2013 Jul; 70():338-47. PubMed ID: 23499664
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.
Xue R; Jin ZL; Chen HX; Yuan L; He XH; Zhang YP; Meng YG; Xu JP; Zheng JQ; Zhong BH; Li YF; Zhang YZ
Eur Neuropsychopharmacol; 2013 Jul; 23(7):728-41. PubMed ID: 22748419
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP
Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Iyengar S; Webster AA; Hemrick-Luecke SK; Xu JY; Simmons RM
J Pharmacol Exp Ther; 2004 Nov; 311(2):576-84. PubMed ID: 15254142
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.
Artaiz I; Zazpe A; Innerárity A; Del Olmo E; Díaz A; Ruiz-Ortega JA; Castro E; Pena R; Labeaga L; Pazos A; Orjales A
Psychopharmacology (Berl); 2005 Nov; 182(3):400-13. PubMed ID: 16032410
[TBL] [Abstract][Full Text] [Related]
9. Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response.
Bacq A; Balasse L; Biala G; Guiard B; Gardier AM; Schinkel A; Louis F; Vialou V; Martres MP; Chevarin C; Hamon M; Giros B; Gautron S
Mol Psychiatry; 2012 Sep; 17(9):926-39. PubMed ID: 21769100
[TBL] [Abstract][Full Text] [Related]
10. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
Stahl SM; Grady MM; Moret C; Briley M
CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213
[TBL] [Abstract][Full Text] [Related]
11. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antidepressant activity of 1-(7-methoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-YL)-cyclohexanol, a β-substituted phenylethylamine in mice.
Dhir A; Malik S; Kessar SV; Singh KN; Kulkarni SK
Eur Neuropsychopharmacol; 2011 Sep; 21(9):705-14. PubMed ID: 21277753
[TBL] [Abstract][Full Text] [Related]
13. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex.
Kihara T; Ikeda M
J Pharmacol Exp Ther; 1995 Jan; 272(1):177-83. PubMed ID: 7815331
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test.
Rénéric JP; Lucki I
Psychopharmacology (Berl); 1998 Mar; 136(2):190-7. PubMed ID: 9551776
[TBL] [Abstract][Full Text] [Related]
15. On the mechanism of antidepressant-like action of berberine chloride.
Kulkarni SK; Dhir A
Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
[TBL] [Abstract][Full Text] [Related]
17. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats.
Mochizuki D; Tsujita R; Yamada S; Kawasaki K; Otsuka Y; Hashimoto S; Hattori T; Kitamura Y; Miki N
Psychopharmacology (Berl); 2002 Jul; 162(3):323-32. PubMed ID: 12122491
[TBL] [Abstract][Full Text] [Related]
19. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
Jensen NH; Rodriguiz RM; Caron MG; Wetsel WC; Rothman RB; Roth BL
Neuropsychopharmacology; 2008 Sep; 33(10):2303-12. PubMed ID: 18059438
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
